Risk‐adapted therapy in follicular lymphoma: Is it time to “FLEX”?
Authors:
Open Access
- 8 October 2020
- journal article
- editorial
- Published by Wiley in American Journal of Hematology
- Vol. 95 (12) , 1454-1456
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (APP1142980)
This publication has 9 references indexed in Scilit:
- Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJournal of Clinical Oncology, 2019
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyThe Lancet Oncology, 2018
- From genetics to the clinic: a translational perspective on follicular lymphomaNature Reviews Cancer, 2018
- The landscape of new drugs in lymphomaNature Reviews Clinical Oncology, 2016
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNAScience Translational Medicine, 2016
- Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryThe Lancet Oncology, 2015
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyJournal of Clinical Oncology, 2015
- Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research NetworkBritish Journal of Cancer, 2015
- Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentationProceedings of the National Academy of Sciences, 2015